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Effects of hepatocyte nuclear factor-1A and -4A on
pancreatic stone protein/regenerating protein and
C-reactive protein gene expression: implications
for maturity-onset diabetes of the young
Ma P Kyithar1†, Caroline Bonner2,4†, Siobhan Bacon1, Seán M Kilbride2, Jasmin Schmid2, Rolf Graf3,
Jochen HM Prehn2 and Maria M Byrne1*
Abstract
Background: There is a significant clinical overlap between patients with hepatocyte nuclear factor (HNF)-1A
and HNF4A maturity-onset diabetes of the young (MODY), two forms of monogenic diabetes. HNF1A and
HNF4A are transcription factors that control common and partly overlapping sets of target genes. We have
previously shown that elevated serum pancreatic stone protein / regenerating protein A (PSP/reg1A) levels
can be detected in subjects with HNF1A-MODY. In this study, we investigated whether PSP/reg is differentially
regulated by HNF1A and HNF4A.
Methods: Quantitative real-time PCR (qPCR) and Western blotting were used to validate gene and protein
expression in cellular models of HNF1A- and HNF4A-MODY. Serum PSP/reg1A levels and high-sensitivity
C-reactive protein (hsCRP) were measured by ELISA in 31 HNF1A- and 9 HNF4A-MODY subjects. The two
groups were matched for age, body mass index, diabetes duration, blood pressure, lipid profile and aspirin
and statin use.
Results: Inducible repression of HNF1A and HNF4A function in INS-1 cells suggested that PSP/reg induction
required HNF4A, but not HNF1A. In contrast, crp gene expression was significantly reduced by repression of
HNF1A, but not HNF4A function. PSP/reg levels were significantly lower in HNF4A subjects when compared
to HNF1A subjects [9.25 (7.85-12.85) ng/ml vs. 12.5 (10.61-17.87) ng/ml, U-test P = 0.025]. hsCRP levels were
significantly lower in HNF1A-MODY [0.22 (0.17-0.35) mg/L] compared to HNF4A-MODY group [0.81 (0.38-1.41)
mg/L, U-test P = 0.002], Parallel measurements of serum PSP/reg1A and hsCRP levels were able to discriminate
HNF1A- and HNF4A-MODY subjects.
Conclusion: Our study demonstrates that two distinct target genes, PSP/reg and crp, are differentially
regulated by HNF1A and HNF4A, and provides clinical proof-of-concept that serum PSP/reg1A and hsCRP
levels may distinguish HNF1A-MODY from HNF4A-MODY subjects.
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Background
Maturity-onset diabetes of the young (MODY) is an
autosomal dominant form of non-ketotic, non-insulin
dependent diabetes that is typically diagnosed before
25 years of age. The majority of MODY subjects are de-
fined by mutations in six specific MODY-related genes,
including the nuclear transcription factors hepatocyte
nuclear factor (HNF)-1A and HNF-4A [1-3]. HNF1A-
MODY represents the most common form of MODY
[3-5]. Mutations in HNF4A are less common than muta-
tions in HNF1A, however over 30 mutations have been
identified to date [6]. HNF1A and HNF4A mutations
cause a similar clinical phenotype of MODY, charac-
terized by progressive beta-cell dysfunction, defects in
glucose-stimulated insulin secretion [7,8] and sensitivity
to low-dose sulphonylureas [9]. However infants with
HNF4A mutations are at risk of developing macrosomia
and transient as well as persistent hyperinsulinaemic
hypoglycaemia [10,11]. Hence specific biomarkers that
would differentiate between HNF1A and HNF4A mu-
tations would facilitate better identification of these
subtypes. In addition, features of HNF1A and HNF4A
mutation carriers tend to overlap with type 1 diabetes,
type 2 diabetes and other monogenic forms of diabetes
[12,13]. Non-specific clinical features of MODY result
in difficulty in selecting the appropriate molecular test-
ing [13]. Sequencing is considered the standard method
for mutation detection in individuals with monogenic
diabetes. However sequencing is expensive and not im-
mediately available in many hospitals.
HNF1A and HNF4A belong to the steroid/thyroid
hormone receptor superfamily of transcription factors
[14]. HNF1A and HNF4A act in a transcription factor
network with HNF4A controlling the activity of HNF1A
[15]. This network plays a fundamental role in the early
development of the pancreas, liver and intestine [16].
Both transcription factors are also important for the
maintenance of beta-cell function throughout life, and
influence the expression of insulin and the principle
glucose transporter Glut2, among many other target
genes [14,17-20]. Molecular studies have demonstrated
that HNF4A-regulated gene expression patterns are
remarkably similar to that of its downstream trans-
cription regulatory protein, HNF1A, and that the two
factors may activate transcription by a synergistic action
[21-23]. We have previously demonstrated that elevated
serum pancreatic stone protein / regenerating protein A
(PSP/reg1A) levels can be detected in subjects with
HNF1A-MODY compared to HNF1A-MODY-negative
non-diabetic family members [24]. We have also shown
that PSP/reg1A levels did not correlate with hypergly-
cemia [25]. Other studies have identified high-sensitivity
C-reactive protein (hsCRP), a known HNF1A target
gene [26,27] to be reduced in serum levels of subjects
with HNF1A-MODY, compared to other forms of dia-
betes such as type 1 diabetes, type 2 diabetes, HNF4A-
MODY, and glucokinase-MODY [28-30]. The concept
that the crp gene is not regulated by HNF4A, despite
HNF1A being downstream of HNF4A, has not yet been
mechanistically proven, and there is evidence for a partial
overlap of hsCRP levels in HNF1A- and HNF4A-MODY
subjects [29,30]. Furthermore, hsCRP levels are elevated
during inflammation, demonstrating the need for ad-
ditional biomarkers. In this study we aimed (i) to investi-
gate whether HNF1A and HNF4A differentially influence
the expression of PSP/reg and crp, and (ii) to provide
clinical proof-of-concept that parallel measurements of
PSP/reg1A and hsCRP levels may be of clinical use in
distinguishing HNF1A- from HNF4A-MODY subjects.
Materials and methods
Inducible repression of HNF1A and HNF4A function in
insulinoma INS-1 cells
Rat INS-1 insulinoma cells overexpressing a dominant-
negative (DN) mutant of HNF1A-MODY (Pro291fsinsC-
HNF1A), carrying a C nucleotide insertion in the polyC-
tract that results in the translation of a truncated
dominant-negative protein, or expressing a dominant
negative mutant of HNF4A (DN-HNF4A), lacking the first
111 amino acids, all under the control of a doxycycline-
dependent transcriptional activator have been described
previously [31-36]. Cells were cultured in RPMI 1640
medium supplemented with 10% FBS (PAA, Cölbe,
Germany), 2 mmol/l L- glutamine, 1 mmol/l pyruvate,
penicillin (100 U/ml), streptomycin (100 μg/ml), 10 mmol/
l HEPES (pH 7.4) and 50 μmol/l 2-mercaptoethanol
(Sigma, Dublin, Ireland) [37]. For experiments, cells were
seeded at a density of 5 × 104 cells/cm2 for 48 h prior to
treatment with / without doxycycline (500 ng/ml), and
were cultured in RPMI 1640 medium containing 6 mmol/
liter glucose and co-treated with reagents as indicated.
Real-time quantitative RT-PCR (qPCR)
Expression patterns of Glut2, insulin, Crp, and PSP/reg
mRNA were examined using real-time qPCR. INS-1 cells
were harvested from culture treatments at the appropriate
time-points. Total RNA was extracted using the RNeasy
mini Kit (Qiagen, Crawley, UK). First-strand cDNA synthe-
sis was performed using 2 μg total RNA as template and
Superscript II reverse transcriptase (Invitrogen) primed
with 50 pmol random hexamers (New England Bio labs,
Ipswich, MA, USA). Quantitative real-time PCR was
performed using the Light Cycler 2.0 (Roche Diagnostics,
Indianapolis, IN, USA) and the QuantiTech SYBR Green
PCR kit (Qiagen) as per manufacturers’ protocols and
25 pmol of primer pair concentration (Sigma-Genosys).
Specific PCR products (150–250 bp in length) for each
gene analysed were designed using Primer3 software
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(http://bioinfo.ut.ee/primer3-0.4.0/) [38]. Sense and anti-
sense primers were designed for all primers
AACAGCACCTTTGTGGTCCT and GTGCAGCAC
TGATCCACAAT for insulin;
CAATTTCATCATCGCCCTCT and GTCTCTGATG
ACCCCAGGAA for Glut2;
GGCTTTGACGCGAATCAGTC and AGTCAGTCA
AGGGCCACAGC for Crp;
AGGCCAGGAGGCTGAAGAAG and TGGAGGCCA
ATCCAGACATT for PSP/reg;
and AGCCATCCAGGCTGTGTTGT and CAGCTGT
GGTGGTGAAGCTG for β-actin.
Western blotting
Cells were rinsed with ice-cold phosphate-buffered sa-
line (PBS) and scraped before being lysed in buffer
containing 62.5 mM Tris-Cl (pH 6.8), 2% SDS, 10%
glycerin and protease inhibitor cocktail (Sigma, Dublin,
Ireland). Protein content was determined using the Pierce
BCA Micro Protein Assay kit (Thermo Fisher Scientific
Inc., Rockford, Illinois). Samples were supplemented with
2-mercaptoethanol (Sigma Aldrich, Dublin, Ireland) and
denaturated at 95°C for 5 min. An equal amount of pro-
tein (25–50 μg) was separated with 12–15% SDS-PAGE
and blotted to nitrocellulose membranes (Protean BA 85;
Schleicher & Schuell, Dassel, Germany). The membranes
were blocked with 1% bovine serum albumin in Tris-
buffered saline (20 mM Tris, pH 7.5, 150 mM NaCl) for
2 h at room temperature. The primary rabbit polyclonal
CRP antibody (Abcam, Cambridge, UK), rabbit polyclonal
anti-PSP/reg antibody [39] and primary mouse monoclo-
nal β-actin mouse antibody were diluted 1:10,000 in 5%
milk (Sigma). The primary mouse monoclonal anti-tubulin
antibody (Sigma) was diluted 1:5,000. Antibodies were in-
cubated overnight at 4 C. The membranes were washed in
Tris-buffered saline containing 0.05% Tween 20. The sec-
ondary antibodies peroxidase-coupled goat anti-rabbit IgG
(Sigma) or goat anti-mouse (Jackson Immunoresearch,
Europe Ltd) were diluted 1:25,000 in the same buffer. The
membranes were washed in Tris-Buffered Saline contai-
ning 0.05% Tween 20. Antibody-conjugated peroxidase
activity was visualized using the Super Signal chemilumin-
escence reagent (Pierce, Buckinghamshire, UK). Densitom-
etry was carried out by quantifying the intensities of bands
using ImageJ 1.41o. Regions were drawn around each band
and the integrated intensity was measured, with intensity of
a background region of the same size on the same gel
subtracted. The intensity of each protein of interest was
divided by the corresponding loading control protein.
Subjects
Subjects with a clinical diagnosis of MODY were recruited
from the diabetes clinics in the Mater Misericordiae
University Hospital Dublin in Ireland. Sequencing of
the HNF1A and HNF4A genes were performed by
IntegraGen (Bonn, Germany) in 2006–2007 and the
Molecular Genetics Laboratory (Exeter, UK) in 2008–
2010. Genetically confirmed MODY patients included
33 cases with HNF1A mutations and 9 with HNF4A mu-
tations. The subjects with HNF1A mutations were from
11 pedigrees and the mutations included L17H, G207D,
P291finsC, S352fsdelG, F426X, P379T, and IVS7-6G > A.
The genotype/phenotype of these patients was published
previously, and all mutations described co-segregated with
diabetes in all pedigrees [40]. Subjects with HNF4A muta-
tions were from 2 pedigrees and the mutations included
M1? and R290C. The genotype/phenotype of these two
pedigrees was published previously and both mutations
likewise co-segregated with diabetes [40]. All subjects
underwent full clinical assessment including a full medical
history and physical examination. Details of the subjects’
weight, height and blood pressure were recorded. Plasma
glucose was measured using Beckman Synchron DXC800
(Beckman Instruments Inc, Brea, USA). Haemoglobin A1c
(HbA1c) was determined by high-performance liquid chro-
matography (Menarini HA81-10, Rome, Italy). The study
was approved by the Research Ethics Committee at the
Mater Misericordiae University Hospital Dublin and all
subjects gave informed written consent.
Measurement of serum PSP/reg1A levels
The enzyme-linked immunosorbent assay (ELISA) was
used to quantify human PSP/reg1A. Recombinant human
PSP/reg1A protein was used to immunize rabbits and
guinea pigs to obtain Antisera [24,39,41]. Serum was
prepared by centrifugation, and the IgG were purified by
affinity chromatography on protein A columns. Subse-
quently, a sandwich ELISA was designed on 96-well ELISA
plates. Antibody of the first species (Guinea pig) was coated
to the bottom, blocked with bovine serum albumin and ali-
quots of serum were then incubated for two hours. After
washing the wells, antibodies of the other species (Rabbit)
were incubated, followed by a series of washing steps. Fi-
nally, a phosphatase-coupled anti-rabbit IgG was used. The
reaction of the phosphatase with a substrate was deter-
mined on a multiplate reader (Dynatech) and subjects’
serum PSP/reg1A levels were compared with standard
amounts of recombinant human PSP/reg1A protein. PSP/
reg1A levels of some of the HNF-1A-MODY subjects are
historic data and have been published previously [24,25].
Measurement of serum hsCRP levels
Serum hsCRP levels were measured using particle en-
hanced immunonephelometry assay (Cardio PhaseW hsCRP,
Siemens) on a Siemens BN II analyzer (Siemens Healthcare
Diagnostics, Deerfield, IL, USA). A typical limit for detec-
tion of hsCRP was 0.175 mg/L for measurements per-
formed using a sample dilution of 1:20. A coefficient of
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variation at the concentration 0.41 mg/L was 7.6%. We
considered that hsCRP values >10 mg/l were likely to rep-
resent an inflammatory response in line with previous stu-
dies [28,42,43]. We therefore performed two separate
analysis approaches, one in which we included (termed ‘all
patients’), and one in which we excluded (termed ‘without
extreme CRP’) the 2 HNF1A-MODY patients with serum
hsCRP values of >10 mg/l.
Statistical analysis
Clinical data are expressed as median and interquartile
range (IQR). Biochemical data are expressed as mean ±
standard error of the means (SEM). Statistical analysis
was performed using SPSS statistical software package
for Windows, version 18.0 (SPSS, Chicago, IL, USA).
The significance of the difference between 2 groups was
determined by Mann–Whitney U test (non-parametric
clinical data) or t test as indicated. For comparisons of
categorical data, chi-square test was applied. The Spearman
correlation test was used for correlation analysis. Dif-
ferences and correlations were considered significant
at P < 0.05.
In order to investigate the performance of hsCRP and
PSP/reg1A to distinguish HNF1A- from HNF4A-MODY
subjects, plots of the receiver operating characteristic
(ROC) were analyzed and linear discriminant analysis
(LDA) was performed. ROC plots were obtained by cal-
culating all sensitivity and specificity pairs for the levels
of serum markers observed in the subjects. An observed
value reaching similarly high sensitivity and specificity
qualified as final cut-off value for classification. LDA was
applied to calculate the best equation for a linear cut-off
function to discriminate between groups. Both approaches
were applied to each serum marker individually and to the
ratio of PSP/reg1A to hsCRP to investigate whether a
combination of the markers improved discrimination.
ROC, LDA and resulting sensitivity and specificity where
assessed using Mat Lab R7.4 (The Math works Inc.,
Natick, MA, USA).
Results
Serum PSP/reg levels may discriminate HNF1A-MODY
from HNF4A-MODY subjects
In a previous study, we have shown that serum levels of
the regenerative protein, PSP/reg1A, were elevated in sub-
jects with HNF1A-MODY when compared to MODY-
negative body mass index (BMI)-, sex-, and age-matched
family members [24]. We were therefore also interested to
determine whether HNF4A-MODY carriers showed simi-
larly elevated serum levels of PSP/reg. Clinical characteris-
tics of HNF1A and HNF4A-MODY subjects are shown in
Table 1. HNF1A-MODY and HNF4A-MODY subjects
were matched for age, BMI, blood pressure, aspirin and
statin use, and white cell and neutrophil counts. HbA1c
values were moderately higher in HNF1A-MODY sub-
jects. We have previously shown that PSP/reg1A levels
did not correlate with HbA1c in HNF1A-MODY [25].
There was no correlation between PSP/reg1A and HbA1c
levels in HNF4A-MODY (rho = 0.56, P = 0.37). There were
no significant differences in duration of diabetes, lipid pro-
file, and fasting plasma glucose between HNF1A-MODY
and HNF4A-MODY groups. Interestingly, we found that
serum PSP/reg1A levels of HNF4A-MODY subjects were
significantly lower than in the HNF1A-MODY subjects
[9.25 (7.85-12.85) ng/ml vs. 12.5 (10.61-17.87) ng/ml, U-
test P = 0.025] (Figure 1). Because PSP/reg1A levels have
been shown to be elevated in HNF1A-MODY as well as
type 1 diabetes patients [24], this suggested that PSP/reg1A
levels may be negatively regulated byHNF4A.
Inhibition of HNF4A, but not HNF1A function decreases
PSP/reg gene expression in INS-1 insulinoma cells
To provide a molecular validation of these clinical findings,
we turned to a cellular model of MODY where suppression
of HNF1A or HNF4A function in INS-1 cells is achieved
through the expression of DN-HNF1A or DN-HNF4A
mutants [21] [33]. The HNF1A and HNF4A dominant-
negative mutants were inducibly expressed in INS-1 cells
using a tetracycline- dependent transactivator system
through the addition of doxycycline for 24 and 48 h. Sup-
pression of either HNF1A or HNF4A function induced a
significant reduction in mRNA levels for Glut2, a known
HNF1A [33] and HNF4A target gene [21] (Figure 2A).
In agreement with previous findings [21] [31,33], insulin
mRNA levels were also significantly reduced during sup-
pression of HNF1A or HNF4A function (Figure 2B).
We next investigated whether suppression of HNF1A
and HNF4A function had a differential effect on PSP/reg
mRNA induction. As reported previously [24], the indu-
cible expression of the DN-HNF1A mutant significantly
elevated PSP/reg mRNA (Figure 3A). Interestingly, sup-
pression of HNF4A function by induction of the DN-
HNF4A mutant led to a significant suppression of PSP/
reg mRNA levels (Figure 3B), demonstrating that HNF4A
negatively regulates PSP/reg mRNA expression. Western
blot analysis indicated similar changes in PSP/reg levels
occurred at the protein level (Figures 3C and 3D). Densi-
tometric analysis of PSP/reg protein levels confirmed
that there was a significant threefold increase in PSP/reg
levels following overexpression of DN-HNF1A (for 48 h),
and a significant decrease in PSP/reg levels following
overexpression of DN-HNF4A (Figures 3E and 3F).
Inhibition of HNF1A, but not HNF4A function decreases
crp expression in INS-1 insulinoma cells
Similar to our clinical observation of altered serum
levels of PSP/reg1A in HNF1A vs. HNF4A-MODY sub-
jects, serum levels of hsCRP have been suggested to be
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reduced in HNF1A- when compared to HNF4A-MODY
subjects [29,30]. To explore whether we were able to de-
tect a similar differential effect of HNF1A and HNF4A
suppression on crp gene expression, we next determined
crp mRNA levels in INS-1 cells inducibly expressing the
HNF1A and HNF4A dominant-negative mutants. As
expected from earlier studies demonstrating that crp is a
HNF1A target gene [26], suppression of HNF1A func-
tion led to a potent down regulation of crp mRNA
(Figure 4A). Interestingly, qPCR analysis of INS-1 cells
with a suppressed HNF4A function demonstrated no
change in crp mRNA expression (Figure 4B). Western
blot analysis indicated similar changes in CRP levels oc-
curred at the protein level (Figure 4C and 4D). Densito-
metric analysis of CRP protein levels confirmed that
there was a significant decrease in CRP levels following
overexpression of DN-HNF1A (for 24 h or 48 h), while
CRP levels were not significantly affected while following
overexpression of DN-HNF4A (Figures 4E and 4F).
hsCRP and PSP/reg1A serum levels may discriminate
HNF1A-MODY and HNF4A-MODY subjects
Having identified two unique target genes of HNF1A and
HNF4A that are differentially controlled by these two
transcription factors, we next determined whether com-
bined measurement of PSP/reg1A and hsCRP levels was
able to discriminate HNF1A from HNF4A subjects. There
was no correlation between hsCRP and HbA1c levels in
HNF1A-MODY (rho = 0.29, P = 0.1) and HNF4A-MODY
subjects (rho = −0.05, P = 0.91). In agreement with
Table 1 Clinical characteristics of HNF1A- and HNF4A-MODY subjects
HNF1A-MODY median (IQR) HNF4A-MODY median (IQR) P value
n (male/female) 33 (14/19) 9 (4/5) 0.91 NS
Age (years) 38 (21–51) 32 (23–46) 0.57 NS
Duration of diabetes (years) 6 (3–18) 7 (0–16) 0.42 NS
Body mass index (kg/m2) 24.4 (22.0–26.2) 23.9 (21.8–25.0) 0.55 NS
Systolic blood pressure (mmHg) 122 (116–131) 115 (109–129) 0.27 NS
Diastolic blood pressure (mmHg) 71 (67–80) 73 (67–79) 0.83 NS
Total cholesterol (mmol/L) 4.3 (3.6–4.9) 3.7 (3.4–4.3) 0.12 NS
LDL cholesterol (mmol/L) 2.5 (2.1–3.0) 2.2 (1.8–2.7) 0.14 NS
HDL cholesterol (mmol/L) 1.3 (1.1–1.7) 1.2 (0.8–1.6) 0.28 NS
TG (mmol/L) 0.71 (0.55–0.92) 0.62 (0.52–0.79) 0.23 NS
HbA1c (%) 7.1 (6.3–8.0) 5.7 (5.3–7.1) 0.045 *
Fasting plasma glucose (mmol/L) 6.8 (5.3–8.6) 5.0 (3.8–7.2) 0.09 NS
WCC (x109/L) 6.76 (5.62–8.52) 6.66 (5.94–7.89) 0.71 NS
Neutrophil count (x109/L) 4.06 (3.30–5.73) 3.70 (3.07–4.47) 0.21 NS
Patients treated with aspirin (n) 10 2 0.63 NS
Patients treated with statin (n) 8 1 0.40 NS
Results are expressed in median and interquartile range (IQR). *: significant; NS: not significant; LDL/HDL: low-density/high-density lipoprotein; TG: triglycerides;
WCC: white cell count; Mann–Whitney U test for HNF1A-MODY vs. HNF4A-MODY revealed no statistically significant differences but for HbA1c. Male/female ratio
and treatment with aspirin or statins were tested for statistical difference using the χ2 test.
HNF4A-MODY HNF1A-MODY0
5
10
15
20
25
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35
40
PS
P 
(ng
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Figure 1 Serum levels of PSP/reg1A in HNF4A-MODY (▲)
versus HNF1A-MODY (○). Solid lines/box plot showing median and
interquartile range and dotted line showing mean. Median of PSP/
reg1A in HNF1A-MODY is 9.25 ng/ml (IQR = 7.85-12.85 ng/ml, n = 9)
while median in HNF1A-MODY is 12.50 ng/ml (IQR = 10.61-17.87 ng/
ml, n = 31). The distributions differ significantly (*): Mann–Whitney
U-test p = 0.025.
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previous studies, we found that serum hsCRP levels were
significantly lower in HNF1A-MODY patients compared
to HNF4A-MODY patients. Serum hsCRP levels of
HNF1A-MODY patients after exclusion of those with
hsCRP levels >10 mg/L were 0.22 (0.17-0.35) mg/L
compared to HNF4A-MODY group [0.81 (0.38-1.41)
mg/L, U-test P = 0.002] (Figure 5A). Serum hsCRP
levels including all HNF1A-MODY patients were 0.22
(0.17-0.38) mg/L and also significantly lower [P = 0.008]
compared to HNF4A-MODY (Figure 5B). However in
both cases, there was a significant overlap of hsCRP
values (Figure 5).
We therefore finally explored in a preliminary statis-
tical analysis whether combined analysis of PSP/reg1A
and hsCRP serum levels could increase the ability of the
individual serum markers to discriminate HNF1A from
HNF4A patients. ROC analysis on all data with the ex-
clusion of the two patients with extreme hsCRP levels
demonstrated that PSP/reg1A showed 90% sensitivity in
identifying HNF1A-MODY patients, but with reduced
specificity (67%) (Additional file 1: Figure S1B). In con-
trast, hsCRP showed a specificity of 89% in identifying
HNF1A-MODY patients, at reduced sensitivity (77%)
though. However when we performed a combined ana-
lysis of PSP/reg1A and hsCRP serum levels (such as the
ratio of PSP/reg1A and hsCRP), we achieved the best
sensitivity and specificity (84%, 26 out of 31 HNF1A
and 89%, 8 out of 9 HNF4A, respectively) (Table 2)
(Additional file 1: Figure S1B). Similar data were calcu-
lated when the ROC analysis was performed on all subjects’
data including those with high hsCRP values (Additional
file 2: Table S1 and Additional file 1: Figure S1A).
We validated these findings by calculating cut-off func-
tions using LDA (Additional file 3: Figure S2). Investi-
gating the discriminatory performance of PSP/reg1A
and hsCRP as individual classifiers to distinguish HNF1A-
from HNF4A-MODY subjects, excluding those with
extreme hsCRP, we found PSP/reg1A to show 45% sensi-
tivity and 67% specificity. The performance of hsCRP
reached a sensitivity of 90%, however correctly detecting
HNF4A-MODY was low with a specificity of 33%. LDA
confirmed results from ROC analysis showing that a com-
bination of both serum markers (for instance the ratio of
PSP/reg1A to hsCRP) resulted in best LDA classification
of 65% sensitivity (20 out of 31 HNF1A) and 89% specifi-
city (8 out of 9 HNF4A) (Table 2). Performing LDA on all
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patient data resulted in similar classification qualities
(Additional file 2).
HNF1A-MODY subjects showed significantly higher
PSP/CRP ratio than HNF4A-MODY subjects [0.06 (0.03-
0.08) vs. 0.01 (0.01-0.02), P = 0.001]. WhenHNF1A-MODY
subjects with extreme hsCRP levels were included, the ratio
is significantly higher (P = 0.003). The median and IQR of
PSP/CRP ratio was unaffected. Further, we investigated the
effects of mutation types. In this study, all mutations in
HNF4A were missense mutations while only 4 HNF1A-
MODY subjects had missense mutations with the remai-
ning 29 subjects having truncatingmutations. We found no
difference between the PSP/CRP ratio in HNF1A-MODY
subjects and mutation type [PSP/CRP ratio in subjects with
missense mutations was 0.015 (0.002-0.069) vs. truncation
mutations 0.062 (0.032-0.077), P = 0.13]. When the 2 pa-
tients with hsCRP >10 mg/L were excluded, one with a
missense mutation and one with a truncation mutation,
median PSP/CRP ratio of missense mutations was 0.025
(0.010-0.092) and of truncation mutations ratio is 0.063
(0.037-0.079). Again, we found no significant increase in
the PSP/CRP ratio with more severe inactivating truncation
mutations inHNF1A-MODY (P = 0.33).
Discussion
The present study provides molecular proof and prelimin-
ary clinical proof-of-concept that the combination of
serum PSP/reg1A and hsCRP levels may be of clinical use
in distinguishing HNF1A-MODY from HNF4A-MODY
subjects. Molecular validation of these clinical findings
validated that HNF1A suppression negatively regulates
crp mRNA and CRP protein levels in INS-1 cells, while
crp gene and protein expression was normal in cells with
a suppressed HNF4A function. Conversely, the induction
of PSP/reg was inhibited by HNF4A suppression, but was
not sensitive to HNF1A suppression. However it should
be noted that overexpression of DN-HNF4A may also
alter the activity of endogenous HNF1A.
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Current guidelines for the genetic diagnosis of MODY
recommend to test for HNF1A mutations if there is a his-
tory of young-onset diabetes before 25 years old in at least
one family member, family history of diabetes (at least two
generations), in the absence of pancreatic islet autoanti-
bodies and without the evidence of insulin resistance [44].
Testing for HNF4A mutations is recommended when
HNF1A genetic analysis does not show a mutation in indi-
viduals with clinical features of MODY or in diabetic family
members with macrosomia or diazoxide-responsive neo-
natal hyperinsulinism [44]. Nevertheless, a recent study
from the UK estimated that more than 80% of MODYcases
are not diagnosed by molecular testing [45].
Barriers to molecular genetic testing include low avail-
ability and high financial cost of genetic testing. The avail-
ability of biomarkers which can be used in combination
with clinical characteristics will enable clinicians to better
identify cases of MODY and/or prioritise DNA testing.
Though DNA sequencing is the ultimate proof of a
genetic mutation, which cannot currently be substituted
by any other test, measurement of PSA/reg1A and hsCRP
levels can be performed to help the clinicians to correctly
and rapidly identify patients with either HNF1A- or
HNF4A-MODY and to aim for genetic counseling. Our
proof-of-concept study suggests that parallel measure-
ments of serum PSP/reg1A and hsCRP levels may be able
to discriminate HNF1A- and HNF4A-MODY subjects
with high confidence. In this study, we have demonstrated
that HNF4A-MODY patients showed significantly lower
levels of serum PSP/reg1A and significantly higher serum
hsCRP levels compared to HNF1A-MODY patients. Our
findings support the previous reported value of hsCRP as
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Figure 4 Suppression of HNF1A, but not HNF4A function leads to a loss of crp expression. DN-HNF1A and DN-HNF4A expression was
induced in INS-1 cells by treatment with 500 ng/ml of doxycycline for 24 and 48 h as indicated. Cells were harvested and total RNA isolated.
(A-B) crp mRNA expression was determined using quantitative real-time PCR following normalization to β-actin. Data are represented as means ±
SEM from n = 3 cultures. The experiment was repeated 3 times with similar results.* p < 0.05 indicates the difference from non-induced controls.
(C-D) Whole cell lysates were analysed by Western blotting on 15% SDS-PAGE. Membranes were probed with an anti-CRP polyclonal antibody.
Antibodies raised against β-actin served as a loading control. (E-F) Quantification of CRP protein levels by densitometry in cells treated with
doxycycline as indicated. Western blots were analysed as described in the Materials and methods section. Data shown represent mean ± SEM
from three independent experiments. *indicates p < 0.05 compared with untreated controls.
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a diagnostic biomarker for HNF1A-MODY vs. HNF4A-
MODY [28-30]. However the above cited earlier studies
observed a significant overlap in hsCRP levels between
these two groups. Therefore, the use of hsCRP as a marker
to identify HNF1A-MODY may yield a high false positive
rate. In addition hsCRP is a major acute-phase plasma
protein which undergoes a rapid and marked rise of its
serum concentration in response to infection or tissue
injury [46]. In previous studies up to 10% of subjects had
hsCRP levels higher 10 mg/L [29,30]. Serial hsCRP mea-
surements would then be required after resolution of the
infection. It has been demonstrated that there may be a
positive correlation between hsCRP and HbA1c when
HbA1c levels are > 9% in type 2 diabetic subjects [47]. In
our study, there is a significant difference in HbA1c levels
between HNF1A-MODY and HNF4A-MODY subjects
even though both groups had relatively low HbA1c levels.
HNF1A-MODY subjects had higher HbA1c levels, yet
their CRP levels were lower than HNF4A-MODY subjects.
We found no association however between hsCRP and
HbA1c levels in HNF1A- and HNF4A-MODY subjects.
It has been previously shown that there was no associ-
ation between hsCRP and HbA1c levels in HNF1A-
MODY patients [28]. However, it is still possible that
utilizing hsCRP as a biomarker alone for diagnosing
HNF1A-MODY in a subject with an HbA1c >9% may
yield a false negative result.
Because of the routine availability of hsCRP testing, the
clinical significance of hsCRP as a marker in identifying
HNF1A-MODY subjects may become significant in the
future. However, the combined detection of hsCRP and
PSP/reg1A levels may provide an improved mean for bet-
ter discrimination of HNF4A and HNF1A subjects.
In our study, we could not confirm PSP/reg and
hsCRP to be normally distributed, which might be due
to our small sample sizes in this proof-of-concept study.
We applied ROC and LDA to investigate the usefulness
of hsCRP and/or PSP/reg as biomarker to distinguish
HNF1A- form HNF4A-MODY. Resulting classification
rules are not optimal, and need to be confirmed in lar-
ger cohorts.
Identification of HNF1A and HNF4A mutation carriers
has significant therapeutic implications as these subjects
show sensitivity to low-dose sulphonylureas and subse-
quent alterations in treatment can improve glycaemic con-
trol in the majority of subjects [48]. HNF4A-MODYcaused
by mutations in the HNF4A gene is relatively less common
thanHNF1Amutations and accounts for approximately 5%
of MODY cases worldwide [44]. However it is likely that
many individuals with HNF4A-MODY remain undiag-
nosed. HNF4A-MODY subjects have similar progressive
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Figure 5 Serum levels of hsCRP in HNF4A-MODY (▲) versus HNF1A-MODY (○). Solid lines/box plot showing median and interquartile
range and dotted line showing mean. (A) Serum levels excluding two subjects with extreme hsCRP levels. Median of hsCRP in HNF4A-MODY is
0.81 mg/l (IQR = 0.38-1.41 mg/l, n = 9), while median in the. HNF1A-MODY (IQR = 0.17-0.35 mg/l, n = 31) is 0.22 mg/l. The distributions differ
significantly (*): Mann–Whitney U-test p = 0.002. (B) Including all hsCRP levels into analysis, increases IQR in HNF1A-MODY (median = 0.22 mg/l,
IQR = 0.17-0.38 mg/l, n = 33). There is a significant difference in medians between HNF1A- and HNF4A-MODY (*): Mann–Whitney U-test p = 0.008.
Table 2 Performance of PSP/reg1A and hsCRP as
individual or combined classifiers to distinguish
HNF1A- from HNF4A-MODY
Classification rule Sensitivity Specificity
ROC: HNF1A if PSP > 9.34 ng/ml 90% 67%
ROC: HNF1A if CRP < 0.36 mg/L 77% 89%
ROC: HNF1A if PSP/CRP > 0.03 84% 89%
LDA: HNF1A if 1.25 - 0.10*PSP < 0 45% 78%
LDA: HNF1A if −0.69 + 0.63*CRP < 0 90% 33%
LDA: HNF1A if 1.17 - 28.25*PSP/CRP < 0 65% 89%
This data excludes the two subjects with extreme hsCRP levels. Classification
rule shows the statistical method and the final rule to determine HNF1A-
MODY. Sensitivity gives the percentage of correctly identified HNF1A-MODY;
specificity shows the percentage of correctly identified HNF4A-MODY.
Kyithar et al. Journal of Translational Medicine 2013, 11:156 Page 9 of 12
http://www.translational-medicine.com/content/11/1/156
diabetic phenotype to HNF1A-MODY subjects, except
that HNF4A mutations are associated with macrosomia,
transient and persistent neonatal hypoglycaemia, later age
of diabetes onset and the absence of low renal threshold
[9,10]. It is crucial to identify HNF4A mutation carriers as
heterozygous mutations in the HNF4A gene in either
parent can impact on pregnancy. The offspring of HNF4A
mutation carriers has a 50% chance of inheriting the muta-
tion from either parent and has the risk of macrosomia due
to increased insulin secretion in utero [11]. Therefore
pre-pregnancy counseling for HNF4A mutation subjects is
required and close monitoring during pregnancy and im-
mediately at birth is needed to minimize complications of
macrosomia and neonatal hypoglycaemia. The potential
biomarkers to differentiate HNF4A-MODY from HNF1A-
MODY would assist in better identification of HNF4A-
MODY subjects and would enable these subjects to receive
appropriate treatment and monitoring prior to and during
the pregnancy to ensure successful maternal and neonatal
outcome.
Of note, our study also confirms the clinical observation
of a differential regulation of crp and PSP/reg genes by
HNF1A and HNF4A on a molecular level. Previous stu-
dies have demonstrated that HNF4A- and HNF1A- regu-
lated gene expression are remarkably similar [21-23], and
that HNF4A acts upstream of HNF1A. Indeed there is
evidence for a cis-acting element located upstream of the
TATA box of the HNF1A promoter that has a high-
affinity-binding site for HNF4A [14]. Previous studies have
shown the presence of putative HNF1A binding elements
within the promoter region of the crp gene, and a loss of
crp expression was shown to be directly linked with al-
tered regulation of HNF1A function [27,28,46]. Interest-
ingly in our experimental studies we showed that INS-1
cells with an inducible suppression of HNF4A function
showed no decrease in crp gene expression. In contrast,
we observed a strong decrease in PSP/reg gene expression
in response to suppression of HNF4A function, compared
to a prominent induction of PSP/reg at the gene and
protein levels during suppression of HNF1A function.
Our study is therefore also one of the first reports that
demonstrate differentially regulated HNF1A and HNF4A
target genes.
Conclusion
In conclusion, our study demonstrates that two distinct
target genes, PSP/reg and crp, are differentially regulated
by HNF1A and HNF4A. We have provided preliminary
clinical proof-of-concept, and have mechanistically vali-
dated that the parallel measurements of serum PSP/reg1A
and hsCRP levels in subjects with clinically suspected
MODY may discriminate HNF1A-MODY from HNF4A-
MODY. Our study therefore warrants clinical validation
of these preliminary findings in a larger cohort of MODY
subjects, as well as type 1 and type 2 diabetes patients.
Additional files
Additional file 1: Figure S1. Receiver operating characteristic (ROC)
analysis testing all observed protein levels as potential thresholds to
distinguish HNF1A- from HNF4A-MODY. A) Analysis of all subjects
indicates ratio of PSP/CRP as the best marker based on the highest area
under the curve (AUC = 0.82, green curve). HNF1A-MODY is predicted
with sensitivity of 79% and specificity of 89% when PSP/CRP ratio >0.03
(threshold 3). CRP reaches AUC = 0.79 (blue curve) and predicts HNF1A
with sensitivity 73% and specificity 89% when using threshold 2. PSP
shows an AUC of 0.76 and high sensitivity of 90% with specificity of 67%
when threshold 1 is used to distinguish HNF1A- from HNF4A-MODY.
B) Excluding the two subjects with extreme CRP levels, ROC analysis
shows similar results but for higher sensitivity. The combination of both
proteins shows highest AUC = 0.88 with sensitivity for HNF1A of 84%
and specificity to predict HNF4A of 89%. CRP reaches AUC = 0.84 and
sensitivity = 77% with specificity = 89% at threshold 2. PSP shows an
AUC of 0.75 with high sensitivity of 90% and specificity 67% when
PSP > 9.34 ng/ml predicts HNF1A-MODY.
Additional file 2: Performance of PSP/reg1A and hsCRP as
individual or combined classifiers to distinguish HNF1A- from
HNF4A-MODY.
Additional file 3: Figure S2. Linear discriminant analysis (LDA)
identifies thresholds to discriminate HNF1A- from HNF4A-MODY.
Double lines on vertical axes represent disruption and change of scale.
A) Analysis of all subjects (including two with extreme CRP levels, red)
results in the best prediction quality for the combination of both
markers. Predicting HNF1A when PSP/CRP ratio > 0.04 has a sensitivity
of 64% and a specificity of 89%. Discriminating based on CRP alone
reaches 89% to predict HNF4A but only 12% for HNF1A, using a CRP
level of 3 mg/l as threshold. A threshold of PSP > 13 ng/ml achieves
prediction of HNF1A with sensitivity 45% and specificity 78%. B) LDA
of the data set excluding the two subjects with extreme CRP levels, finds
similar results for analysis but for CRP as marker. As in A), combination
performs best with specificity 89% and sensitivity 65% when PSP/CRP
ratio >0.04 is predicted as HNF1A. CRP < 1.25 mg/l correctly predicts 90%
of HNF1A subjects, but at the same time only 33% of HNF4A. Using PSP
< 12.5 ng/ml as threshold discriminates 45% of HNF1A correctly from
78% of HNF4A subjects.
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